The use of a cosmetic product in dermatological therapy fulfills very well the need, felt for example in recurring pathologies, to alternate or juxtapose more important therapeutic cycles with agents which are able to rebalance as well as protect epidermic integrity. A new emollient and antierythematous cosmetic preparation based on dimethyloxobenzasilane (Lenolia A/O) has recently been the object of dermatologists' attention. This clinical trial was aimed at assessing its primary irritant power. The epicutaneous test was carried out according to an experimental design controlled with respect to the vehicle. The trials were carried out at the Allergology Department of the Dermatology Institute at the University of Milan. Fifty out-patients (18 M, 32 F) of mean age 41.9 years, were selected among those having to undergo epicutaneous tests, using the substances included in the GIRDCA series: the substances to be tested were placed in Finn-Chambers on the skin of the back. Forty-eight and 72 hours after application, the severity of erythema, oedema, pain, burning and itching were assessed. In only one case was there any irritation due to the product being studied, but not to its vehicle; the components responsible for the episode were not identified. Overall the preparation was well tolerated.
|Translated title of the contribution||Clinical study to evaluate the allergenicity of Lenolia A/O emollient cream after a single application (patch-test)|
|Number of pages||4|
|Journal||Giornale Italiano di Dermatologia e Venereologia|
|Publication status||Published - 1997|
ASJC Scopus subject areas